Verrica Pharmaceuticals Inc
NASDAQ:VRCA

Watchlist Manager
Verrica Pharmaceuticals Inc Logo
Verrica Pharmaceuticals Inc
NASDAQ:VRCA
Watchlist
Price: 0.694 USD 2.66% Market Closed
Market Cap: 62.8m USD
Have any thoughts about
Verrica Pharmaceuticals Inc?
Write Note

Verrica Pharmaceuticals Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Verrica Pharmaceuticals Inc
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Verrica Pharmaceuticals Inc
NASDAQ:VRCA
Cost of Revenue
-$2.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Cost of Revenue
-$27B
CAGR 3-Years
3%
CAGR 5-Years
0%
CAGR 10-Years
-2%
Bristol-Myers Squibb Co
NYSE:BMY
Cost of Revenue
-$11.4B
CAGR 3-Years
-6%
CAGR 5-Years
-10%
CAGR 10-Years
-11%
Pfizer Inc
NYSE:PFE
Cost of Revenue
-$17.5B
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
-6%
Merck & Co Inc
NYSE:MRK
Cost of Revenue
-$14.8B
CAGR 3-Years
-2%
CAGR 5-Years
-2%
CAGR 10-Years
2%
Eli Lilly and Co
NYSE:LLY
Cost of Revenue
-$7.8B
CAGR 3-Years
-4%
CAGR 5-Years
-11%
CAGR 10-Years
-4%
No Stocks Found

Verrica Pharmaceuticals Inc
Glance View

Market Cap
62.8m USD
Industry
Pharmaceuticals

Verrica Pharmaceuticals, Inc. engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 38 full-time employees. The company went IPO on 2018-06-15. The firm is focused on developing and commercializing treatments for skin diseases. The firm's lead product candidate, VP-102, is a drug-device combination of its topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, administered through its single-use precision applicator. The company is developing VP-102 for the treatment of molluscum contagiosum (molluscum), a highly contagious and primarily pediatric viral skin disease, external genital warts and common warts. The company also intends to develop its second cantharidin-based product candidate, VP-103, for the treatment of plantar warts, which are warts located on the bottom of the foot. The company also intends to develop its third product candidate, LTX-315, for the treatment of dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma.

VRCA Intrinsic Value
1.338 USD
Undervaluation 48%
Intrinsic Value
Price

See Also

What is Verrica Pharmaceuticals Inc's Cost of Revenue?
Cost of Revenue
-2.4m USD

Based on the financial report for Sep 30, 2024, Verrica Pharmaceuticals Inc's Cost of Revenue amounts to -2.4m USD.

What is Verrica Pharmaceuticals Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
-97%

Over the last year, the Cost of Revenue growth was -97%.

Back to Top